Cancer Blog
- Dr. Robert Nagourney -

Patients with advanced malignancies often seek the expertise of physicians at major institutions.

Although she showed some response, her disease persisted and she was being considered for surgery to remove the residual tumor...

George Brown is alive today because our laboratory analysis identified a simple 2 drug combination that now one else thought to give him.

This patient had recurrent breast cancer that upon biopsy proved to be triple negative.

Personalized treatment means more cured patients. More people survive cancer when our Functional Profiling system is used before treatment.

However, a new dilemma has arisen; the failure of surgeons to comply with Pancreatic Cancer patient’s wishes to have tissue submitted.

Here in 2023, we suddenly discover that TIL cells are highly active against cancer, but it was Steven Rosenberg who first described it.

There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.

One noteworthy case was a 78-year-old patient successfully treated without surgery.

Extremely rare liver cancer that mostly affects people in their twenties associated with a gene rearrangement, mostly lethal, until now.

Patients are being encouraged to contact the researchers to get biopsies and help take charge of their disease.

At the 2023 American Association for Cancer Research meeting in Orlando, we reported results of ex vivo analysis of programmed cell death.

Combining Functional Profiling with Nagourney Cancer Institute's 11,000 patient studies provides personalized cancer treatment plans.

Cancer patients must take charge of their disease. If they are well, regardless of their condition, they should look for options.

We take a different approach to the treatment of cancer – based on profiling how our patients’ cancerous cells will respond to treatment.

After the recommended treatment, FOLFIRINOX, using his tissue we suggested new classes of drugs that target P53 and MEK/ERK.

2022 Reflection. Among our most important accomplishments in 2022 was the installation of a world-class Mass Spectrometry research program.

I applaud anything that accelerates clinical development, but once again the focus is almost exclusively genomic.

Over time I came to realize that the role of the infectious disease expert was not to add antibiotics but to subtract them.

Can rare tumors offer the way forward? This optimism comes from the fact that not unlike CML, rare cancers may carry unique insights.